# TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study

Study · id `cardio:ct-nct07821008` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07821008](<https://clinicaltrials.gov/study/NCT07821008>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07821008

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 274 participants.

## Technical summary

Registry record NCT07821008. Randomized; double masking; primary purpose treatment. Start 2026-11-24 (anticipated); primary completion 2029-12-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 274 participants (planned count; ClinicalTrials.gov record NCT07821008, source copy `cardio:ctgov-nct07821008-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2026-11-24 (anticipated) (ClinicalTrials.gov record NCT07821008, source copy `cardio:ctgov-nct07821008-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2029-12-14 (anticipated) (ClinicalTrials.gov record NCT07821008, source copy `cardio:ctgov-nct07821008-2026-11-06`, retrieved 2026-11-18)
- Completion: 2029-12-14 (anticipated) (ClinicalTrials.gov record NCT07821008, source copy `cardio:ctgov-nct07821008-2026-11-06`, retrieved 2026-11-18)
- Countries: France (ClinicalTrials.gov record NCT07821008, source copy `cardio:ctgov-nct07821008-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07821008-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
- Acronym: TALISCHER-SAH
- Condition: Subarachnoid Hemorrhage, Aneurysmal
- Condition: Brain Ischemia
- Condition: Endovascular Procedure
- Intervention (Drug): Experimental group: ticagrelor
- Intervention (Drug): Control group: placebo
- Lead sponsor: University Hospital, Toulouse
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as the lead sponsor: University Hospital, Toulouse (`cardio:org-university-hospital-toulouse`)

## Provenance

Content hash: 08dbb10f111c2c8374da497d89c841483c32d0c7dbc9f82f33ed6ba18008e3da
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
